U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H38F6O3
Molecular Weight 524.5792
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of FALECALCITRIOL

SMILES

C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)C[C@H](O)C3=C

InChI

InChIKey=XPYGGHVSFMUHLH-UUSULHAXSA-N
InChI=1S/C27H38F6O3/c1-16(6-4-13-25(36,26(28,29)30)27(31,32)33)21-10-11-22-18(7-5-12-24(21,22)3)8-9-19-14-20(34)15-23(35)17(19)2/h8-9,16,20-23,34-36H,2,4-7,10-15H2,1,3H3/b18-8+,19-9-/t16-,20-,21-,22+,23+,24-/m1/s1

HIDE SMILES / InChI

Molecular Formula C27H38F6O3
Molecular Weight 524.5792
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 2
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including http://link.springer.com/article/10.1007/s007740050027 http://www.ncbi.nlm.nih.gov/pubmed/15632470

Falecalcitriol is an analog of calcitriol. Falecalcitriol was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on Apr 4, 2001. It was co-developed by Taisho, Dainippon Sumitomo and Kissei, then marketed as Hornel by Taisho and Taisho Toyama or as Fulstan by Dainippon Sumitomo Pharma and Kissei in JP. It has a higher potency both in vivo and in vitro systems, and longer duration of action in vivo. This medicine improves bone disease and symptoms caused by shortage of vitamin D, etc. It also prompts calcium absorption to supply lacked calcium and prevents bone-thinning. It is usually used to treat secondary hyperparathyroidism under maintenance dialysis, hypoparathyroidism, rickets or osteomalacia. Falecalcitriol regulates the proliferation of parathyroid cells and parathyroid hormone synthesis possibly via binding to a nuclear receptor for vitamin D (VDR). It is often not possible to administer doses high enough to sufficiently inhibit parathyroid hormones because of the risk of hypercalcemia and hyperphosphatemia.

Approval Year

Conditions
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
28 pg/mL
2 μg single, oral
dose: 2 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
FALECALCITRIOL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
15 h
2 μg single, oral
dose: 2 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
FALECALCITRIOL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.3 ug 1 times / day multiple, oral
Studied dose
Dose: 0.3 ug, 1 times / day
Route: oral
Route: multiple
Dose: 0.3 ug, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: FED
Sources:
Other AEs: Hypercalcemia, anorexia...
Other AEs:
Hypercalcemia (9 patients)
anorexia (1 pt)
Sources:
2 ug single, oral
Studied dose
Dose: 2 ug
Route: oral
Route: single
Dose: 2 ug
Sources:
healthy
Health Status: healthy
Sex: unknown
Food Status: UNKNOWN
Sources:
AEs

AEs

AESignificanceDosePopulation
anorexia 1 pt
0.3 ug 1 times / day multiple, oral
Studied dose
Dose: 0.3 ug, 1 times / day
Route: oral
Route: multiple
Dose: 0.3 ug, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: FED
Sources:
Hypercalcemia 9 patients
0.3 ug 1 times / day multiple, oral
Studied dose
Dose: 0.3 ug, 1 times / day
Route: oral
Route: multiple
Dose: 0.3 ug, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: FED
Sources:
PubMed

PubMed

TitleDatePubMed
Synthesis and biological evaluations of A-ring isomers of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3.
2000 Aug
Enhanced coactivator binding and transcriptional activation of mutant vitamin D receptors from patients with hereditary 1,25-dihydroxyvitamin D-resistant rickets by phosphorylation and vitamin D analogs.
2005 Sep
Patents

Patents

Sample Use Guides

The recommended dose is 0.3 μg once daily for secondary hyperparathyroidism and 0.3-0.9 μg once daily for hypoparathyroidism, rickets or osteomalacia.
Route of Administration: Oral
In Vitro Use Guide
1,25(OH)2 D3 decreased the expression of ERbeta proteins in smooth muscle cells and increased the ERalpha isoform in E304 cells by 40% to 75%
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:05:39 GMT 2025
Edited
by admin
on Mon Mar 31 18:05:39 GMT 2025
Record UNII
G70A8514T8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FALECALCITORIOL
JAN  
Preferred Name English
FALECALCITRIOL
INN   JAN   MART.   WHO-DD  
INN  
Official Name English
ST630
Code English
FALECALCITRIOL [JAN]
Common Name English
RO 23-4194
Code English
RO234194
Code English
Falecalcitriol [WHO-DD]
Common Name English
falecalcitriol [INN]
Common Name English
FALECALCITORIOL [JAN]
Common Name English
(+)-(5Z,7E)-26,26,26,27,27,27-HEXAFLUORO-9,10-SECOCHOLESTA-5,7,10(19)-TRIENE-1.ALPHA.,3.BETA.,25-TRIOL
Common Name English
ST-630
Code English
FALECALCITRIOL [MART.]
Common Name English
FLOCALCITRIOL
Common Name English
HORNEL
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C39713
Created by admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
Code System Code Type Description
INN
7103
Created by admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
PRIMARY
EPA CompTox
DTXSID601027560
Created by admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
PRIMARY
EVMPD
SUB07498MIG
Created by admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
PRIMARY
PUBCHEM
5282190
Created by admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
PRIMARY
DRUG CENTRAL
1127
Created by admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
PRIMARY
MESH
C040488
Created by admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
PRIMARY
ChEMBL
CHEMBL2106158
Created by admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
PRIMARY
SMS_ID
100000081532
Created by admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
PRIMARY
CAS
83805-11-2
Created by admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
PRIMARY
FDA UNII
G70A8514T8
Created by admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
PRIMARY
NCI_THESAURUS
C80884
Created by admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
PRIMARY
WIKIPEDIA
FALECALCITRIOL
Created by admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
MAJOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
MINOR
TARGET -> AGONIST
METABOLIC ENZYME -> SUBSTRATE
MINOR
METABOLIC ENZYME -> SUBSTRATE
MINOR
Related Record Type Details
ACTIVE MOIETY